U.S. Gene Therapy Company Executive Couple Sells Millions in Shares Near Stock Peak

Krystal Biotech, Inc. (Nasdaq: KRYS) CEO Krish S. Krishnan and R&D President Suma M. Krishnan each sold approximately 29,000 and 27,000 shares of the company’s common stock in multiple transactions on June 4 under a pre-established Rule 10b5-1 trading plan. They disposed of their shares at prices in the $300 range per share, generating proceeds of several million dollars (tens of billions of Korean won). Following the sales, they continue to hold roughly 1.45 million and 1.38 million shares, respectively, through a combination of direct ownership and family trusts.

In its Q1 2026 earnings report, the company disclosed that sales of its flagship gene therapy VYJUVEK reached about $116.4 million (approximately KRW 163 billion), a year-over-year increase of over 30%, and that it held around $1 billion (about KRW 1.4 trillion) in cash and investments as of quarter‐end. Analysts note that institutional ownership has been rising rapidly and that KRYS shares have been trading around $300, near their 52-week highs.

Krystal Biotech is a commercial‐stage gene therapy company based in Pittsburgh, focused on treatments for rare skin disorders. Its lead product, VYJUVEK, is a topical gene therapy approved for the treatment of wounds in patients with dystrophic epidermolysis bullosa. The company is also advancing its gene‐delivery platform into other indications—including cystic fibrosis, non-small cell lung cancer, and various skin and epithelial disorders—and has received FDA platform technology and RMAT designations for multiple pipeline candidates.